Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular risk

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,011 result(s) found for: Cardiovascular risk. Displaying page 1 of 51.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001891-21 Sponsor Protocol Number: NC25608 Start Date*: 2012-02-21
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary H...
    Medical condition: Patients with stable CHD, CHD risk equivalents (including PAD, cerebrovascular disease, and T2D), or at elevated risk for CV mortality and morbidity on the basis of multiple risk factors for CVD by...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000215-89 Sponsor Protocol Number: CL2-16257-099 Start Date*: 2013-06-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, d...
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012269-71 Sponsor Protocol Number: BC22140 Start Date*: 2010-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
    Medical condition: Type 2 diabetes patients with a recent acute coronary syndrome (ACS) event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) DK (Prematurely Ended) FR (Completed) IE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002644-32 Sponsor Protocol Number: EFC14875 Start Date*: 2017-11-14
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Ca...
    Medical condition: Type 2 diabetes mellitus Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LV (Completed) GB (Completed) HU (Completed) SE (Completed) NO (Completed) FR (Completed) NL (Completed) DK (Completed) ES (Prematurely Ended) LT (Completed) EE (Completed) PT (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-002466-35 Sponsor Protocol Number: ACTRN012607000099426 Start Date*: 2008-03-11
    Sponsor Name:Imperial Ciollege [...]
    1. Imperial Ciollege
    2. St Mary's NHS Trust
    3. University Medical Center Utrecht
    Full Title: A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007638-21 Sponsor Protocol Number: CR2 Start Date*: 2008-09-04
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian Health Board
    Full Title: Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients?
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035523 Platelet analyses HLT
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003946-34 Sponsor Protocol Number: OB-401 Start Date*: 2013-10-30
    Sponsor Name:VIVUS, Inc.
    Full Title: A Qsymia™ CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease
    Medical condition: Cardiovascular Disease in overweight and obese subjects
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003486-26 Sponsor Protocol Number: 1002-047 Start Date*: 2017-05-24
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Ad...
    Medical condition: Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004393-22 Sponsor Protocol Number: LIB003-006 Start Date*: 2022-01-13
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea...
    Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002006-27 Sponsor Protocol Number: CKJX839B12302 Start Date*: 2021-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease...
    Medical condition: Atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002630-32 Sponsor Protocol Number: NN6435-4697 Start Date*: 2021-07-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: Dose response and safety of an oral PCSK9i, NNC0385-0434, in patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk on maximally tolerated statin dose and other lipi...
    Medical condition: Established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk Elevated cholesterol
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.1 10022891 - Investigations 10005425 Blood cholesterol increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017242-30 Sponsor Protocol Number: D5132C00001 Start Date*: 2010-12-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Sali...
    Medical condition: Myocardial Infarction, Cardiovascular Death, Atherothombosis, Stroke
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) RO (Completed) CZ (Completed) SK (Completed) PL (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) NO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-002871-20 Sponsor Protocol Number: LIB003-012 Start Date*: 2022-04-21
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Open Label, Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) compared to Inclisiran in Patients With Cardiovascular Disease, or at High Risk for Cardiovascula...
    Medical condition: Patients with atherosclerotic cardiovascular (CV) disease (ASCVD) or high risk of ASCVD who need additional LDL-C reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012140-16 Sponsor Protocol Number: 28431754DIA3008 Start Date*: 2010-01-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus and history or high risk cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    19.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) HU (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001241-24 Sponsor Protocol Number: CFTY720D2409 Start Date*: 2014-07-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod
    Medical condition: Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018173-31 Sponsor Protocol Number: POISE-2 Start Date*: 2011-02-25
    Sponsor Name:Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    Full Title: Ensayo clínico factorial de clonidina y aspirina en pacientes que van a ser sometidos a cirugía no cardiaca y que estén en riesgo moderado o alto de sufrir eventos cardíacos perioperatorios (Estudi...
    Medical condition: Prevención de episodios cardiovasculares en pacientes de moderado a alto riesgo cardiovascular que son sometidos a una cirugía no cardiaca.
    Disease: Version SOC Term Classification Code Term Level
    9 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DK (Completed) GB (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000575-17 Sponsor Protocol Number: FENOPRA-III-12-1 Start Date*: 2012-10-22
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose co...
    Medical condition: mixed dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    16.0 10027433 - Metabolism and nutrition disorders 10070901 Diabetic dyslipidaemia PT
    16.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002670-39 Sponsor Protocol Number: PROXI2017 Start Date*: 2018-02-01
    Sponsor Name:Bispebjerg Hospital
    Full Title: Hyperoxia and antioxidant intervention during major non-cardiac surgery and risk of cerebral and cardiovascular complications, a blinded 2x2 factorial randomized clinical trial
    Medical condition: Patients undergoing major non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10007654 Cardiovascular injuries HLT
    20.0 10042613 - Surgical and medical procedures 10064939 Cardiovascular event prophylaxis PT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    20.0 100000004849 10032964 Other symptoms involving cardiovascular system LLT
    20.0 100000004869 10078955 Cardiovascular risk LLT
    20.0 10042613 - Surgical and medical procedures 10052616 Intraoperative care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004394-49 Sponsor Protocol Number: LIB003-007 Start Date*: 2021-08-12
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at ...
    Medical condition: Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 11:46:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA